Pharmaceutical Research and Manufacturers of America
Pharmaceutical Research and Manufacturers of America (PhRMA), founded in 1958, is a trade group representing the pharmaceutical research and biotechnology companies in the United States. PhRMA's stated mission is advocacy for public policies that encourage the discovery of new medicines for patients by pharmaceutical and biotechnology research companies. PhRMA's current CEO is John J. Castellani.
On its website, PhRMA states its "mission is winning advocacy for public policies that encourage the discovery of life-saving and life-enhancing new medicines for patients by pharmaceutical / biotechnology research companies. To accomplish this mission, PhRMA is dedicated to achieving in Washington, D.C., the states and the world:[1]
- "Broad patient access to safe and effective medicines through a free market, without price controls,
- "Strong intellectual property incentives, and
- "Transparent, efficient, regulation and a free flow of information to patients."
Mission
PhRMA's mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients by pharmaceutical/biotechnology research companies.
Research and development
In 2009, PhRMA members alone invested an estimated $45.8 billion in discovering and developing new medicines. Industry-wide research and investment reached a record $65.3 billion in 2009.
Issues
Doha
PhRMA has worked to minimize the effect of the Doha Declaration by the Doha round of negotiations. The Doha Declaration issued in November 2001, indicated that TRIPs should not prevent states from dealing with public health crises. The health crises specifically addressed by the declaration include the AIDS epidemic.[2]
Depression in the workplace
In June 2004, PhRMA teamed up with the U.S. Chamber of Commerce and the American Psychiatric Association "to demonstrate the cost of depression in the workplace and to show employers that treating affected workers would improve the bottom line." The three groups endorsed a "depression calculator," which allows employers to estimate the effect of untreated depression on their company's profits, through absenteeism and low productivity. The calculator also figures "how much the business would save if employees were treated."[3] The Arizona-based "health-care consulting firm" The HSM Group organized the calculator's public "introduction." At the press conference unveiling the calculator, PhRMA's senior vice president for policy, research and strategic planning, Richard Smith, said: "A depressed employee is less productive or absent for 30 to 50 days a year. ... The person's medical costs are $2,000 to $3,000 more than other employees."
Programs
SMARxT Disposal
SMARxT Disposal is a joint program run by the U.S. Fish and Wildlife Service, the American Pharmacists Association, and PhRMA to encourage consumers to properly dispose of unused medicines in order to avoid harm to the environment.[4]
Partnership for Prescription Assistance
The Partnership for Prescription Assistance is a program by PhRMA and its member companies that connects patients in-need with information on low-cost and free prescription medication.[4]
Members
Some prominent members of PhRMA include the following. A full list of members is available at the PhRMA website.[5]
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly and Company
- Genzyme Corporation
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Sanofi-Aventis
See also
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Food and Drug Administration (FDA, USA)
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
- Japan Pharmaceutical Manufacturers Association (JPMA)
- Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme
- SAFE-BioPharma Association (SAFE)
References
- ^ "Mission Statement". PhRMA. Retrieved 2011-02-06.
- ^ http://en.wikipedia.org/wiki/Agreement_on_Trade-Related_Aspects_of_Intellectual_Property_Rights#Controversy
- ^ "Productivity Impact Model: Calculating the Impact of Depression in the Workplace and the Benefits of Treatment". PhRMA. Retrieved 2007-05-14.
- ^ a b "Patient Resrouces". Pharmaceutical Research and Manufacturers of America. Retrieved 6 April 2011.
- ^ [1]